- Home
- GTN vs KROS Comparison
GTN vs KROS Comparison
Compare GTN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTN
- KROS
- Stock Information
- Founded
- GTN 1897
- KROS 2015
- Country
- GTN United States
- KROS United States
- Employees
- GTN N/A
- KROS N/A
- Industry
- GTN Broadcasting
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- GTN Industrials
- KROS Health Care
- Exchange
- GTN Nasdaq
- KROS Nasdaq
- Market Cap
- GTN 523.7M
- KROS 565.0M
- IPO Year
- GTN N/A
- KROS 2020
- Fundamental
- Price
- GTN $4.60
- KROS $15.22
- Analyst Decision
- GTN Strong Buy
- KROS Buy
- Analyst Count
- GTN 4
- KROS 14
- Target Price
- GTN $6.88
- KROS $20.56
- AVG Volume (30 Days)
- GTN 899.4K
- KROS 1.1M
- Earning Date
- GTN 11-07-2025
- KROS 11-06-2025
- Dividend Yield
- GTN 6.96%
- KROS N/A
- EPS Growth
- GTN 1482.23
- KROS N/A
- EPS
- GTN 1.53
- KROS 0.47
- Revenue
- GTN $3,549,000,000.00
- KROS $232,844,000.00
- Revenue This Year
- GTN N/A
- KROS $6,657.47
- Revenue Next Year
- GTN $13.18
- KROS N/A
- P/E Ratio
- GTN $3.00
- KROS $32.70
- Revenue Growth
- GTN 7.03
- KROS 85820.30
- 52 Week Low
- GTN $2.91
- KROS $9.12
- 52 Week High
- GTN $6.31
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- GTN 37.89
- KROS 49.86
- Support Level
- GTN $4.33
- KROS $14.77
- Resistance Level
- GTN $4.93
- KROS $15.30
- Average True Range (ATR)
- GTN 0.18
- KROS 0.65
- MACD
- GTN -0.00
- KROS 0.02
- Stochastic Oscillator
- GTN 42.19
- KROS 75.17
About GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.